Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report diagnosed influenza event rates for each country, as well as annualized events projected to the national population.

Patient populations are forecast over a period of 10 years.

Clarivate Epidemiology’s influenza forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of influenza over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides 10 years of forecast data for the following influenza patient population:

  • Diagnosed influenza event rates.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson…